DSGN — Design Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $692.58m
- $472.73m
Annual cashflow statement for Design Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -35.5 | -63.3 | -66.9 | -49.6 | -69.8 |
| Depreciation | |||||
| Non-Cash Items | 4.61 | 9.53 | 7.04 | 6.88 | 11.7 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.42 | 2.05 | 0.728 | -0.993 | 3.11 |
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -29.4 | -51.3 | -58.6 | -43.1 | -54.4 |
| Capital Expenditures | -1.54 | -0.918 | -0.256 | -0.34 | -0.193 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -52.1 | -220 | 52.8 | 44.3 | 23.1 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -53.6 | -221 | 52.5 | 44 | 22.9 |
| Financing Cash Flow Items | — | -0.427 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 379 | 0.235 | 0.724 | 0.513 | 25.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 296 | -272 | -5.3 | 1.36 | -5.71 |